– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which ...
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF ...
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously ...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc ...
3. Conditional Election of Ronald W. Miller For: 622,082 / 81.22% Against: 143,840 / 18.78% 4. Conditional Election of Ulrich Kosciessa For: 620,608 / 81.03% Against: 145,314 / 18.97% 5. Conditional ...
– In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical ...
The Medical University of South Carolina (MUSC) and Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) have announced that the Company has agreed to transfer its discovery library of ...
QUEBEC CITY, April 11 - AEterna Zentaris a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that David J. Mazzo, Ph.D., has resigned as President and Chief ...
Summerville biopharmaceutical firm Aeterna Zentaris has agreed to pay $6.5 million to settle a class-action lawsuit filed by shareholders who claim the company misled them about the safety and ...
CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results